Last reviewed · How we verify

NCT05497271

Confirmation of Association Between Cystic Fluid Analysis With Pancreatic Cystic Lesions

Status unknown Last updated 12 August 2022
What this trial tests

trial in Pancreatic Cyst in 500 participants. Status unknown.

Timeline
1 January 2017
Primary endpoint
31 December 2025
31 December 2025

Quick facts

Lead sponsorSeoul National University Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment500
Start date1 January 2017
Primary completion31 December 2025
Estimated completion31 December 2025
Sites1 location across South Korea

Conditions studied

Sponsor

Seoul National University Hospital

Who can join

18 and older, any sex, with Pancreatic Cyst or Molecular, Chemical Analysis of Cystic Fluid. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Through a comprehensive analysis of the pancreatic cystic fluid analysis, the role of the cystic fluid analysis is confirmed in terms of accurate diagnosis of pancreatic cysts, appropriate prediction of treatment response, and to select proper treatment indication through analytic results.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Pancreatic Cyst

Currently open trials in the same condition.

Other Seoul National University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05497271.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing